drugset / Trial / NCT06233994
A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized, open-label study to evaluate the safety and efficacy of ZG005 in combination with Donafenib or Bevacizumab in patients with advanced hepatocellular carcinoma.
Timeline
- Start
- 2024-01
- Primary completion
- 2026-01
- Completion
- 2026-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Donafenib | Small molecule | 0.2 g | Oral |
| Subject | ZG005 | Unknown | 10 mg/kg | Intravenous |